Stage T3 prostate cancer: A nonrandomized comparison between definitive irradiation and induction hormonal manipulation plus prostatectomy

Urology

Volumn 51, Issue 5, 1998, Pages 782-787

  Corn, Benjamin W ^a   Valicenti, Richard K ^a   Mulholland, S Grant ^a   Hyslop, Theresa ^a   Gomella, Leonard ^a  

^a THOMAS JEFFERSON UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROGEN; FLUTAMIDE; LEUPRORELIN; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CLINICAL ARTICLE; CLINICAL TRIAL; COLLIMATOR; CONTROLLED STUDY; HUMAN; HUMAN TISSUE; MALE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATECTOMY; RADIATION DOSE; SCORING SYSTEM;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANALYSIS OF VARIANCE; ANDROGEN ANTAGONISTS; ANTINEOPLASTIC AGENTS, HORMONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, ADJUVANT; DISEASE-FREE SURVIVAL; DOSE FRACTIONATION; FLUTAMIDE; FORECASTING; HUMANS; LEUPROLIDE; LYMPH NODE EXCISION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROSTATE-SPECIFIC ANTIGEN; PROSTATECTOMY; PROSTATIC NEOPLASMS; RADIOTHERAPY DOSAGE; TREATMENT OUTCOME;

EID: 0031776590     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00022-3     Document Type: Article

References (27)

1. Beahrs OH, Henson DE, Hutter RVP, Kennedy BJ. Manual for Staging of Cancer. 4th ed. 1992;487-512 JB Lippincott, Philadelphia.
2. Corn BW, Hanks GE. Management of stage T3 adenocarcinoma of the prostate. Raghavan D, Scher H, Leiber SA, Lange P. Principles and Practices of Genitourinary Oncology. 1997;541-552 JB Lippincott, Philadelphia.
3. Hanks GE. The prostate. Moss WT, Cox JC. Radiation Oncology. 6th ed. 1989;487 CV Mosby, St Louis.
4. Morgan WR, Bergstrahl EJ, Zincke H. Long-term evaluation of radical prostatectomy as treatment for clinical stage C (T3) prostate cancer. Urology. 41:1993;113-120.
5. Zincke H. Bilateral pelvic lymphadenectomy and radical retropubic prostatectomy for stage C or D1 adenocarcinoma of the prostate possible beneficial effect of adjuvant treatment . NCI Monograph. 7:1988;109-115.
6. Gomella LG, Liberman SN, Mulholland SG, Petersen RO, Hyslop T, Corn BW. Induction androgen deprivation plus prostatectomy for stage T3 disease failure to achieve prostate-specific antigen-based freedom from disease status in a phase II trial . Urology. 47:1996;870-877.
7. Rubin P, Constine LS, Fajardo LF, Phillips TL, Wasserman TH, Bartelink H. Joint statement of mission by the RTOG/EORTC working groups. Int J Radiat Oncol Biol Phys. 31:1995;1037-1039.
8. Lerner SE, Blute ML, Zincke H. Extended experience with radical prostatectomy for clinical stage T3 prostate cancer outcome and contemporary morbidity . J Urol. 154:1995;1447-1452.
9. Corn BW, Hanks GE, Schultheiss TE, Hunt MA, Lee WR, Coia LR. Conformal treatment of prostate cancer with improved targeting superior prostate-specific antigen response compared to standard treatment . Int J Radiat Oncol Biol Phys. 32:1995;325-330.
10. Lee WR, Hanks GE, Schultheiss TE, Corn BW, Hunt MA. Localized prostate cancer treated by external-beam radiotherapy alone serum prostate-specific antigen-driven outcome analysis . J Clin Oncol. 13:1995;464-469.
11. Cancer Fact and Figures-1995. 1995;American Cancer Society, Atlanta.
12. Shipley WU, Verhey LJ, Munzenrider JE, Suit HD, Urie MM, McMannus PL, Young RH, Shipley JW, Zietman AL, Biggs PJ, et al. Advanced prostate cancer the results of a randomized comparative trial of high dose irradiation boosting with conformal protons compared with conventional dose irradiation using photons alone . Int J Radiat Oncol Biol Phys. 32:1995;3-12.
13. Russell KJ, Laramore GE, Krall JM, Thomas FJ, Maor MH, Hendrickson FR, Krieger JN, Griffen TW. Eight years experience with neutron radiotherapy in the treatment of stages C and D prostate cancer updated results of the RTOG 77-04 randomized clinical trial . Prostate. 11:1987;183-193.
14. Wallner K, Roy J, Harrison L. Tumor control and morbidity following transperineal iodine 125 implantation for stage T1/T2 prostatic carcinoma. J Clin Oncol. 14:1996;449-453.
15. Corn BW, Hanks GE, Lee WR, Schultheiss TE. Does the current subclassification of stage T3 adenocarcinoma of the prostate have clinical relevance? Urology. 45:1995;484-489.
16. Pilepich MV, Krall J, Al-Sarraf Roach M, Doggett RLS, Sause W. A phase III trial of androgen suppression before and during radiation therapy for locally advanced prostatic carcinoma preliminary report of RTOG protocol 8610 . Proc Am Soc Clin Oncol. 12:1993;229.
17. Pilepich MV, Buzydlowski JW, John MJ, Rubin P, McGowan DG, Marcial VA. Phase II trial of hormonal cytoreduction with megesterol and diethylstilbestrol in conjunction with radiotherapy for carcinoma of the prostate outcome of RTOG 83-07 . Int J Radiat Oncol Biol Phys. 32:1995;175-180.
18. Labrie F, Cusan L, Gomez J, Diamond P, Suburu R, Martin L. Down staging of early stage prostate cancer before radical prostatectomy the first randomized trial of neoadjuvant combination therapy with flutamide and a luteinizing hormone-releasing hormone agonist . Urology. 44:1994;29-36.
19. Soloway MS, Sharifi R, Wajsman Z, McLeod D, Wood DP Jr, Puras-Baez A. Randomized prospective study comparing radical prostatectomy alone versus radical prostatectomy preceded by androgen blockade in clinical stage B2 (T2bNxM0) prostate cancer. J Urol. 154:(2 Pt 1):1995;424-428.
20. Fair WR, Aprikian A, Sogani P, Reuter V, Whitmore WF Jr. The role of neoadjuvant hormonal manipulation in localized prostatic cancer. Cancer. 71:(3 suppl):1993;1031-1038.
21. Van Poppel H, De Ridder D, Elgamal AA, Van de Voorde W, Werbrouck P, Ackaert K, Oyen R, Pittomvils G, and Baert L, for the Belgian Uro-Oncological Study Group: Neoadjuvant hormonal therapy before radical prostatectomy decreases the number of positive surgical margins in stage T2 prostate cancer: interim results of a prospective randomized trial. J Urol 154: 429-434, 1995.
22. Zagars GK, Geara FB, Pollack A, von Eschenback AC. The T classification of clinically localized prostate cancer an appraisal based on disease outcome after radiation therapy . Cancer. 73:1994;1904-1912.
23. Bagshaw MA. Potential for radiotherapy alone in prostatic cancer. Cancer. 55:1995;2079-2085.
24. Hanks GE, Asbell S, Krall JM, Perez CA, Doggett S, Rubin P, Sause W, Pilepich MV. Outcome for lymph node dissection negative T1b, T2 (A2, B) prostate cancer treated with external beam radiation therapy in RTOG 77-06. Int J Radiat Oncol Biol Phys. 21:1991;1099-1103.
25. Hanks GE, Perez CA, Kozar M, Asbell SO, Pilepich MV, Pajak TF. PSA confirmation of cure at 10 years of T1B, T2, N0, M0 prostate cancer patients treated in RTOG protocol 7706 with external beam irradiation. Int J Radiat Oncol Biol Phys. 30:1994;289-292.
26. Horwitz EM, Vicini FA, Ziaja EL, Gonzalez J, Dmuchowski CF, Stromberg JS, Brabbins DS, Hollander J, Chen PY, Martinez AA. Assessing the variability of outcome for patients treated with localized prostate irradiation using different definitions of biochemical control. Int J Radiat Oncol Biol Phys. 36:1996;565-571.
27. McLaughlin PW, Sandler HM, Jiroutek MR. Prostate-specific antigen following prostate radiotherapy how long can you go? J Clin Oncol. 14:1996;2889-2892.